{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T03:25:03Z","timestamp":1782789903538,"version":"3.54.5"},"reference-count":173,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.lfs.2024.122697","type":"journal-article","created":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T08:39:26Z","timestamp":1714984766000},"page":"122697","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Androgen receptor: Structure, signaling, function and potential drug discovery biomarker in different breast cancer subtypes"],"prefix":"10.1016","volume":"348","author":[{"given":"Nirali","family":"Shukla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanisha","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepshikha","family":"Rathore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinal","family":"Soni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jigna","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemangini","family":"Vora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heena","family":"Dave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2024.122697_bb0005","series-title":"Global Cancer Burden Growing, Amidst Mounting Need for Services","author":"W.H. Organization","year":"2024"},{"key":"10.1016\/j.lfs.2024.122697_bb0010","doi-asserted-by":"crossref","first-page":"209","DOI":"10.5306\/wjco.v13.i3.209","article-title":"Breast cancer in India: present scenario and the challenges ahead","volume":"13","author":"Mehrotra","year":"2022","journal-title":"World J Clin Oncol"},{"key":"10.1016\/j.lfs.2024.122697_bb0015","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1200\/EDBK_350358","article-title":"Personalizing adjuvant endocrine therapy for early-stage hormone receptor\u2013positive breast cancer","volume":"42","author":"Pistilli","year":"2022","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.lfs.2024.122697_bb0020","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/cac2.12358","article-title":"Breast cancer: an up-to-date review and future perspectives","volume":"42","author":"Hong","year":"2022","journal-title":"Cancer Commun."},{"key":"10.1016\/j.lfs.2024.122697_bb0025","doi-asserted-by":"crossref","first-page":"594","DOI":"10.6004\/jnccn.2023.0031","article-title":"NCCN Guidelines\u00ae Insights: Breast Cancer, Version 4.2023: featured updates to the NCCN guidelines","volume":"21","author":"Gradishar","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.lfs.2024.122697_bb0030","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1002\/cncr.34158","article-title":"Abbreviated endocrine therapy duration for low estrogen receptor-positive breast cancer: the counter to extended endocrine therapy","volume":"128","author":"Poterala","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.lfs.2024.122697_bb0035","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/path.4280","article-title":"Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes","volume":"232","author":"Lehmann","year":"2014","journal-title":"J. Pathol."},{"key":"10.1016\/j.lfs.2024.122697_bb0040","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.lfs.2024.122697_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/bcr3421","article-title":"Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15","volume":"15","author":"Lehmann-Che","year":"2013","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.lfs.2024.122697_bb0050","doi-asserted-by":"crossref","first-page":"e1123","DOI":"10.1016\/j.clbc.2018.03.012","article-title":"Feasibility of classification of triple negative breast cancer by immunohistochemical surrogate markers","volume":"18","author":"Kim","year":"2018","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.lfs.2024.122697_bb0055","first-page":"42","article-title":"Current strategies for targeting the activity of androgen receptor variants, Asian","volume":"6","author":"Armstrong","year":"2019","journal-title":"J. Urol."},{"key":"10.1016\/j.lfs.2024.122697_bb0060","article-title":"Early-stage triple-negative breast cancer journey: beginning, end, and everything in between","volume":"43","author":"Han","year":"2023","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.lfs.2024.122697_bb0065","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1210\/er.2001-0031","article-title":"Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone","volume":"24","author":"Labrie","year":"2003","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.lfs.2024.122697_bb0070","doi-asserted-by":"crossref","first-page":"594","DOI":"10.3389\/fendo.2018.00594","article-title":"The divergent function of androgen receptor in breast cancer; analysis of steroid mediators and tumor intracrinology","volume":"9","author":"Bleach","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.lfs.2024.122697_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/bcr2413","article-title":"Androgens and the breast","volume":"11","author":"Dimitrakakis","year":"2009","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.lfs.2024.122697_bb0080","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/01.GME.0000055522.67459.89","article-title":"A physiologic role for testosterone in limiting estrogenic stimulation of the breast","volume":"10","author":"Dimitrakakis","year":"2003","journal-title":"Menopause"},{"key":"10.1016\/j.lfs.2024.122697_bb0085","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1096\/fj.99-0863com","article-title":"Testosterone inhibits estrogen-induced mammary epithelial proliferation and suppresses estrogen receptor expression","volume":"14","author":"Zhou","year":"2000","journal-title":"FASEB J."},{"key":"10.1016\/j.lfs.2024.122697_bb0090","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1002\/ijc.28528","article-title":"Premenopausal serum sex hormone levels in relation to breast cancer risk, overall and by hormone receptor status\u2014results from the EPIC cohort","volume":"134","author":"Kaaks","year":"2014","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.lfs.2024.122697_bb0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/bcr3394","article-title":"Premenopausal endogenous steroid hormones and breast cancer risk: results from the Nurses\u2019 Health Study II","volume":"15","author":"Fortner","year":"2013","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.lfs.2024.122697_bb0100","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/j.breast.2013.07.007","article-title":"Sex hormones and breast cancer risk and prognosis","volume":"22","author":"Folkerd","year":"2013","journal-title":"Breast"},{"key":"10.1016\/j.lfs.2024.122697_bb0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/bcr3632","article-title":"Sex hormone associations with breast cancer risk and the mediation of randomized trial postmenopausal hormone therapy effects","volume":"16","author":"Zhao","year":"2014","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.lfs.2024.122697_bb0110","doi-asserted-by":"crossref","first-page":"424","DOI":"10.3390\/ijms23010424","article-title":"The other side of the coin: may androgens have a role in breast cancer risk?","volume":"23","author":"Chiodo","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2024.122697_bb0115","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41416-021-01392-z","article-title":"Endogenous hormones and risk of invasive breast cancer in pre-and post-menopausal women: findings from the UK Biobank","volume":"125","author":"Tin Tin","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lfs.2024.122697_bb0120","first-page":"6533","article-title":"The role of the androgen receptor signaling in breast malignancies","volume":"37","author":"Christopoulos","year":"2017","journal-title":"Anticancer Res."},{"key":"10.1016\/j.lfs.2024.122697_bb0125","doi-asserted-by":"crossref","first-page":"492","DOI":"10.3389\/fendo.2018.00492","article-title":"The androgen receptor in breast cancer","volume":"9","author":"Giovannelli","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.lfs.2024.122697_bb0130","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ctrv.2018.06.005","article-title":"Androgen receptor in triple negative breast cancer: a potential target for the targetless subtype","volume":"68","author":"Gerratana","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.lfs.2024.122697_bb0135","doi-asserted-by":"crossref","DOI":"10.1621\/nrs.06008","article-title":"Diverse roles of androgen receptor (AR) domains in AR-mediated signaling","volume":"6","author":"Claessens","year":"2008","journal-title":"Nucl. Recept. Signal."},{"key":"10.1016\/j.lfs.2024.122697_bb0140","doi-asserted-by":"crossref","first-page":"T161","DOI":"10.1530\/ERC-14-0243","article-title":"Complexities of androgen receptor signalling in breast cancer","volume":"21","author":"McNamara","year":"2014","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.lfs.2024.122697_bb0145","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1080\/10408363.2019.1575643","article-title":"Androgen receptor: a promising therapeutic target in breast cancer","volume":"56","author":"Vasiliou","year":"2019","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"10.1016\/j.lfs.2024.122697_bb0150","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00795-010-0494-3","article-title":"Androgens in human breast carcinoma","volume":"43","author":"Suzuki","year":"2010","journal-title":"Med. Mol. Morphol."},{"key":"10.1016\/j.lfs.2024.122697_bb0155","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.yfrne.2007.10.005","article-title":"Non-genomic actions of androgens","volume":"29","author":"Foradori","year":"2008","journal-title":"Front. Neuroendocrinol."},{"key":"10.1016\/j.lfs.2024.122697_bb0160","first-page":"187","article-title":"Androgen receptor-mediated non-genomic regulation of prostate cancer cell proliferation","volume":"2","author":"Liao","year":"2013","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.lfs.2024.122697_bb0165","doi-asserted-by":"crossref","first-page":"R485","DOI":"10.1530\/ERC-16-0190","article-title":"Androgen receptor signaling pathways as a target for breast cancer treatment","volume":"23","author":"Pietri","year":"2016","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.lfs.2024.122697_bb0170","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1093\/hmg\/ddt077","article-title":"Androgen receptor-induced tumor suppressor, KLLN, inhibits breast cancer growth and transcriptionally activates p53\/p73-mediated apoptosis in breast carcinomas","volume":"22","author":"Wang","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.lfs.2024.122697_bb0175","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/j.ddmec.2012.11.003","article-title":"The role of androgen receptor in breast cancer","volume":"9","author":"Iacopetta","year":"2012","journal-title":"Drug Discov Today Dis Mech"},{"key":"10.1016\/j.lfs.2024.122697_bb0180","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1093\/annonc\/mdy024","article-title":"Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis","volume":"29","author":"Bareche","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lfs.2024.122697_bb0185","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.pharmthera.2019.05.005","article-title":"Consideration of breast cancer subtype in targeting the androgen receptor","volume":"200","author":"Venema","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.lfs.2024.122697_bb0190","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/aps.2014.18","article-title":"Androgen receptor: structure, role in prostate cancer and drug discovery","volume":"36","author":"Tan","year":"2015","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.lfs.2024.122697_bb0195","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1146\/annurev-pharmtox-052220-015912","article-title":"A new old target: androgen receptor signaling and advanced prostate cancer","volume":"62","author":"Westaby","year":"2022","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.lfs.2024.122697_bb0200","first-page":"2330","article-title":"Immunohistochemical, genetic and epigenetic profiles of hereditary and triple negative breast cancers","volume":"5","author":"Murria","year":"2015","journal-title":"Relevance in personalized medicine, Am J Cancer Res"},{"key":"10.1016\/j.lfs.2024.122697_bb0205","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1159\/000484300","article-title":"Androgen receptor expression and bicalutamide antagonize androgen receptor inhibit \u03b2-catenin transcription complex in estrogen receptor-negative breast cancer","volume":"43","author":"Huang","year":"2017","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.lfs.2024.122697_bb0210","doi-asserted-by":"crossref","first-page":"6131","DOI":"10.1158\/0008-5472.CAN-09-0452","article-title":"Androgen receptor inhibits estrogen receptor-\u03b1 activity and is prognostic in breast cancer","volume":"69","author":"Peters","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.lfs.2024.122697_bb0215","doi-asserted-by":"crossref","first-page":"R335","DOI":"10.1530\/ERC-17-0108","article-title":"Allosteric alterations in the androgen receptor and activity in prostate cancer","volume":"24","author":"Uo","year":"2017","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.lfs.2024.122697_bb0220","doi-asserted-by":"crossref","first-page":"T199","DOI":"10.1530\/ERC-16-0298","article-title":"Emerging data on androgen receptor splice variants in prostate cancer","volume":"23","author":"Cao","year":"2016","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.lfs.2024.122697_bb0225","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-11-0141","article-title":"Alternatively spliced androgen receptor variants","volume":"18","author":"Dehm","year":"2011","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.lfs.2024.122697_bb0230","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s12672-014-0177-y","article-title":"The link between androgen receptor splice variants and castration resistant prostate cancer","volume":"5","author":"Sprenger","year":"2014","journal-title":"Horm Cancer"},{"key":"10.1016\/j.lfs.2024.122697_bb0235","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1158\/0008-5472.CAN-08-2764","article-title":"Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer","volume":"69","author":"Hu","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.lfs.2024.122697_bb0240","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ccr.2009.02.021","article-title":"Regulation of androgen receptor transcriptional activity and specificity by RNF6-induced ubiquitination","volume":"15","author":"Xu","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.lfs.2024.122697_bb0245","doi-asserted-by":"crossref","first-page":"19736","DOI":"10.1074\/jbc.M112.352930","article-title":"Androgen receptor splice variants activate androgen receptor target genes and support aberrant prostate cancer cell growth independent of canonical androgen receptor nuclear localization signal","volume":"287","author":"Chan","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.lfs.2024.122697_bb0250","doi-asserted-by":"crossref","first-page":"580","DOI":"10.4103\/1008-682X.178490","article-title":"Development of AR-V7 as a putative treatment selection marker for metastatic castration-resistant prostate cancer","volume":"18","author":"Luo","year":"2016","journal-title":"Asian J. Androl."},{"key":"10.1016\/j.lfs.2024.122697_bb0255","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1158\/1541-7786.MCR-16-0236","article-title":"Interplay between cytoplasmic and nuclear androgen receptor splice variants mediates castration resistance","volume":"15","author":"Zhan","year":"2017","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.lfs.2024.122697_bb0260","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.1158\/0008-5472.CAN-15-0381","article-title":"Androgen receptor splice variants dimerize to transactivate target genes","volume":"75","author":"Xu","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.lfs.2024.122697_bb0265","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1038\/s41388-020-01585-5","article-title":"A detailed characterization of stepwise activation of the androgen receptor variant 7 in prostate cancer cells","volume":"40","author":"Roggero","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.lfs.2024.122697_bb0270","doi-asserted-by":"crossref","first-page":"4704","DOI":"10.1158\/1078-0432.CCR-17-0017","article-title":"Androgen receptor variant AR-V9 is coexpressed with AR-V7 in prostate cancer metastases and predicts abiraterone resistance","volume":"23","author":"Kohli","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lfs.2024.122697_bb0275","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1002\/pros.21382","article-title":"A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities","volume":"71","author":"Hu","year":"2011","journal-title":"Prostate"},{"key":"10.1016\/j.lfs.2024.122697_bb0280","doi-asserted-by":"crossref","unstructured":"H.M.L. Kallio, R. Hieta, L. Latonen, A. Brofeldt, M. Annala, K. Kivinummi, T.L. Tammela, M. Nykter, W.B. Isaacs, H.G. Lilja, G.S. Bova, T. Visakorpi, Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases, British Journal of Cancer 2018 119:3 119 (2018) 347\u2013356. doi:https:\/\/doi.org\/10.1038\/s41416-018-0172-0.","DOI":"10.1038\/s41416-018-0172-0"},{"key":"10.1016\/j.lfs.2024.122697_bb0285","doi-asserted-by":"crossref","first-page":"R123","DOI":"10.1530\/ERC-22-0019","article-title":"Dysregulation of splicing variants and spliceosome components in breast cancer","volume":"29","author":"Gahete","year":"2022","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.lfs.2024.122697_bb0290","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.3390\/ijms25031817","article-title":"Treatments targeting the androgen receptor and its splice variants in breast cancer","volume":"25","author":"Tien","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2024.122697_bb0295","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1084\/jem.20031233","article-title":"Abnormal mammary gland development and growth retardation in female mice and MCF7 breast cancer cells lacking androgen receptor","volume":"198","author":"Yeh","year":"2003","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.lfs.2024.122697_bb0300","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.3390\/jcm9041083","article-title":"Influence of androgen receptor on the prognosis of breast cancer","volume":"9","author":"Hwang","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.lfs.2024.122697_bb0305","doi-asserted-by":"crossref","unstructured":"A. Anestis, I. Zoi, A.G. Papavassiliou, M. V. Karamouzis, Androgen receptor in breast cancer\u2014clinical and preclinical research insights, Molecules 2020, Vol. 25, Page 358 25 (2020) 358. doi:https:\/\/doi.org\/10.3390\/MOLECULES25020358.","DOI":"10.3390\/molecules25020358"},{"key":"10.1016\/j.lfs.2024.122697_bb0310","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/bcr3619","article-title":"Estrogen receptor beta as a novel target of androgen receptor action in breast cancer cell lines","volume":"16","author":"Rizza","year":"2014","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.lfs.2024.122697_bb0315","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djt319","article-title":"Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis","volume":"106","author":"Vera-Badillo","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.lfs.2024.122697_bb0320","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1158\/1078-0432.CCR-16-1095","article-title":"High estrogen receptor \u00df expression is prognostic among adjuvant chemotherapy\u2013treated patients\u2014results from a population-based breast cancer cohort","volume":"23","author":"Elebro","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lfs.2024.122697_bb0325","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1038\/emboj.2011.216","article-title":"Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1","volume":"30","author":"Robinson","year":"2011","journal-title":"EMBO J."},{"key":"10.1016\/j.lfs.2024.122697_bb0330","first-page":"47","article-title":"ARE we there yet?","volume":"6","author":"Michmerhuizen","year":"2020","journal-title":"Understanding androgen receptor signaling in breast cancer, NPJ Breast Cancer"},{"key":"10.1016\/j.lfs.2024.122697_bb0335","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10549-009-0436-8","article-title":"Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells","volume":"121","author":"De Amicis","year":"2010","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.lfs.2024.122697_bb0340","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0082650","article-title":"The impact of androgen receptor expression on breast cancer survival: a retrospective study and meta-analysis","volume":"8","author":"Qu","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2024.122697_bb0345","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920958355","article-title":"Role of androgen receptor expression in early stage ER+\/PgR\u2212\/HER2\u2013breast cancer","volume":"12","author":"Tagliaferri","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.lfs.2024.122697_bb0350","article-title":"Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers","volume":"124","author":"Castellano","year":"2010","journal-title":"Springer"},{"key":"10.1016\/j.lfs.2024.122697_bb0355","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1158\/1078-0432.CCR-16-0979","article-title":"The prognostic role of androgen receptor in patients with early-stage breast cancer: a meta-analysis of clinical and gene expression data","volume":"23","author":"Bozovic-Spasojevic","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lfs.2024.122697_bb0360","doi-asserted-by":"crossref","first-page":"134","DOI":"10.4048\/jbc.2015.18.2.134","article-title":"Influence of androgen receptor expression on the survival outcomes in breast cancer: a meta-analysis","volume":"18","author":"Kim","year":"2015","journal-title":"J. Breast Cancer"},{"key":"10.1016\/j.lfs.2024.122697_bb0365","doi-asserted-by":"crossref","unstructured":"T.E. Hickey, L.A. Selth, K.M. Chia, G. Laven-Law, H.H. Milioli, D. Roden, S. Jindal, M. Hui, J. Finlay-Schultz, E. Ebrahimie, S.N. Birrell, S. Stelloo, R. Iggo, S. Alexandrou, C.E. Caldon, T.M. Abdel-Fatah, I.O. Ellis, W. Zwart, C. Palmieri, C.A. Sartorius, A. Swarbrick, E. Lim, J.S. Carroll, W.D. Tilley, The androgen receptor is a tumor suppressor in estrogen receptor\u2013positive breast cancer, Nature Medicine 2021 27:2 27 (2021) 310\u2013320. doi:https:\/\/doi.org\/10.1038\/s41591-020-01168-7.","DOI":"10.1038\/s41591-020-01168-7"},{"key":"10.1016\/j.lfs.2024.122697_bb0370","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/1393505","article-title":"Evaluation of androgen receptor in relation to estrogen receptor (AR\/ER) and progesterone receptor (AR\/PgR): a new must in breast cancer?","volume":"2019","author":"Bronte","year":"2019","journal-title":"J. Oncol."},{"key":"10.1016\/j.lfs.2024.122697_bb0375","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13058-020-01369-5","article-title":"Quadruple-negative breast cancer: novel implications for a new disease","volume":"22","author":"Bhattarai","year":"2020","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.lfs.2024.122697_bb0380","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/modpathol.2011.54","article-title":"Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses\u2019 Health Study","volume":"24","author":"Collins","year":"2011","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.lfs.2024.122697_bb0385","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/bcr1122","article-title":"Identification of molecular apocrine breast tumours by microarray analysis","volume":"7","author":"Farmer","year":"2005","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.lfs.2024.122697_bb0390","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.4155\/cli.12.88","article-title":"Elucidating the role of androgen receptor in breast cancer","volume":"2","author":"Lim","year":"2012","journal-title":"Clin Investig (Lond)"},{"key":"10.1016\/j.lfs.2024.122697_bb0395","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-14607-2","article-title":"Targeting androgen receptor in treating HER2 positive breast cancer","volume":"7","author":"He","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lfs.2024.122697_bb0400","doi-asserted-by":"crossref","unstructured":"S. Orr\u00f9, E. Pascariello, G. Sotgiu, D. Piras, L. Saderi, M.R. Muroni, C. Carru, C. Arru, C. Mocci, G. Pinna, R. Barbara, P. Cossu-Rocca, M.R. de Miglio, Prognostic role of androgen receptor expression in HER2+ breast carcinoma subtypes, Biomedicines 2022, Vol. 10, Page 164 10 (2022) 164. doi:https:\/\/doi.org\/10.3390\/BIOMEDICINES10010164.","DOI":"10.3390\/biomedicines10010164"},{"key":"10.1016\/j.lfs.2024.122697_bb0405","article-title":"Abstract P1-08-23: androgen receptor as predictive marker for pathologic complete response in breast cancer with neoadjuvant chemotherapy","volume":"82","author":"Lee","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.lfs.2024.122697_bb0410","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3390\/jpm12020261","article-title":"Androgen receptor: a new marker to predict pathological complete response in HER2-positive breast cancer patients treated with Trastuzumab Plus Pertuzumab Neoadjuvant therapy","volume":"12","author":"Li","year":"2022","journal-title":"J Pers Med"},{"key":"10.1016\/j.lfs.2024.122697_bb0415","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1530\/ERC-19-0315","article-title":"The prognostic value of androgen receptor (AR) in HER2-enriched metastatic breast cancer","volume":"27","author":"Wang","year":"2020","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.lfs.2024.122697_bb0420","article-title":"Quadruple-negative breast cancer: an uneven playing field","volume":"6","author":"Saini","year":"2020","journal-title":"JCO Glob Oncol"},{"key":"10.1016\/j.lfs.2024.122697_bb0425","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ccr.2011.05.026","article-title":"Targeting androgen receptor in estrogen receptor-negative breast cancer","volume":"20","author":"Ni","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.lfs.2024.122697_bb0430","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1593\/neo.101324","article-title":"A feedback loop between androgen receptor and ERK signaling in estrogen receptor-negative breast cancer","volume":"13","author":"Chia","year":"2011","journal-title":"Neoplasia"},{"key":"10.1016\/j.lfs.2024.122697_bb0435","doi-asserted-by":"crossref","DOI":"10.3390\/cancers9010004","article-title":"Expression and clinical significance of androgen receptor in triple-negative breast cancer","volume":"9","author":"Asano","year":"2017","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.lfs.2024.122697_bb0440","doi-asserted-by":"crossref","DOI":"10.3390\/healthcare9030277","article-title":"Correlation between androgen receptor expression and immunohistochemistry type as prognostic factors in a cohort of breast cancer patients: result from a single-center, cross sectional study","volume":"9","author":"Ni\u021b\u0103","year":"2021","journal-title":"Healthcare"},{"key":"10.1016\/j.lfs.2024.122697_bb0445","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/s41416-019-0630-3","article-title":"Androgen receptor expression and response to chemotherapy in breast cancer patients treated in the neoadjuvant TECHNO and PREPARE trial","volume":"121","author":"Witzel","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lfs.2024.122697_bb0450","article-title":"Importance of predictive biomarkers related to pharmacogenetics in breast cancer and prostate: a systematic review","volume":"10","author":"Menezes","year":"2021","journal-title":"Research, Society and Development"},{"key":"10.1016\/j.lfs.2024.122697_bb0455","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.semcancer.2019.04.002","article-title":"Androgen receptor in breast cancer: a wolf in sheep\u2019s clothing?","volume":"60","author":"Salvi","year":"2020","journal-title":"A lesson from prostate cancer, Semin Cancer Biol"},{"key":"10.1016\/j.lfs.2024.122697_bb0460","doi-asserted-by":"crossref","first-page":"S157","DOI":"10.1016\/S0090-8258(21)00941-0","article-title":"Expression of androgen receptor splice variant, AR-V7, in high-grade serous ovarian cancer","volume":"162","author":"Wilson","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.lfs.2024.122697_bb0465","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clgc.2019.09.015","article-title":"Androgen receptor splice variant, AR-V7, as a biomarker of resistance to androgen axis-targeted therapies in advanced prostate cancer","volume":"18","author":"Zhang","year":"2020","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.lfs.2024.122697_bb0470","first-page":"61","article-title":"Identification of androgen receptor splice variant transcripts in breast cancer cell lines and human tissues, Horm","volume":"5","author":"Hu","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.lfs.2024.122697_bb0475","doi-asserted-by":"crossref","unstructured":"D.C. Ferguson, D.A. Mata, T.K. Tay, T.A. Traina, A. Gucalp, S. Chandarlapaty, T.M. D'Alfonso, E. Brogi, K. Mullaney, M. Ladanyi, M.E. Arcila, R. Benayed, D.S. Ross, Androgen receptor splice variant-7 in breast cancer: clinical and pathologic correlations, Modern Pathology 2021 35:3 35 (2021) 396\u2013402. doi:https:\/\/doi.org\/10.1038\/s41379-021-00924-5.","DOI":"10.1038\/s41379-021-00924-5"},{"key":"10.1016\/j.lfs.2024.122697_bb0480","doi-asserted-by":"crossref","first-page":"6398","DOI":"10.1158\/1538-7445.AM2022-6398","article-title":"Abstract 6398: functional characterization of Androgen Receptor splice variants in breast cancer invasion and metastasis","volume":"82","author":"Srivastava","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.lfs.2024.122697_bb0485","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0197827","article-title":"Androgen receptor positive triple negative breast cancer: clinicopathologic, prognostic, and predictive features","volume":"13","author":"Astvatsaturyan","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2024.122697_bb0490","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/bjc.2015.434","article-title":"Clinical verification of sensitivity to preoperative chemotherapy in cases of androgen receptor-expressing positive breast cancer","volume":"114","author":"Asano","year":"2016","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lfs.2024.122697_bb0495","doi-asserted-by":"crossref","first-page":"46482","DOI":"10.18632\/oncotarget.10208","article-title":"Prognostic value of androgen receptor in triple negative breast cancer: a meta-analysis","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.lfs.2024.122697_bb0500","doi-asserted-by":"crossref","first-page":"995","DOI":"10.3390\/cancers11070995","article-title":"Prognostic role of androgen receptor in triple negative breast cancer: a multi-institutional study","volume":"11","author":"Bhattarai","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.lfs.2024.122697_bb0505","doi-asserted-by":"crossref","first-page":"452","DOI":"10.3389\/fonc.2019.00452","article-title":"Androgen receptor expression and association with distant disease-free survival in triple negative breast cancer: analysis of 263 patients treated with standard therapy for stage I-III disease","volume":"9","author":"Dieci","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lfs.2024.122697_bb0510","doi-asserted-by":"crossref","first-page":"P3","DOI":"10.1158\/1538-7445.SABCS16-P3-05-07","article-title":"Abstract P3-05-07: flutamide reduced tumor progression and altered steroid hormone secretion in human and canine inflammatory breast cancer cell lines","volume":"77","author":"Caceres","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.lfs.2024.122697_bb0515","doi-asserted-by":"crossref","first-page":"108","DOI":"10.2174\/1574884714666190112151202","article-title":"Efficacy and safety of Nilutamide in patients with metastatic prostate cancer who underwent orchiectomy: a systematic review and meta-analysis","volume":"14","author":"Rashid","year":"2019","journal-title":"Curr. Clin. Pharmacol."},{"key":"10.1016\/j.lfs.2024.122697_bb0520","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1080\/14737140.2018.1503954","article-title":"Apalutamide for the treatment of prostate cancer","volume":"18","author":"Rathkopf","year":"2018","journal-title":"Expert. Rev. Anticancer. Ther."},{"key":"10.1016\/j.lfs.2024.122697_bb0525","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS20-PS12-05","article-title":"Abstract PS12-05: first efficacy results of a 2-stage Simon\u2019s design randomised phase 2 of darolutamide or capecitabine in patients with triple-negative, androgen receptor positive advanced breast cancer (UCBG06-3)","volume":"81","author":"Bonnefoi","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.lfs.2024.122697_bb0530","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2147\/DDDT.S15850","article-title":"Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer","author":"Rehman","year":"2012","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.lfs.2024.122697_bb0535","doi-asserted-by":"crossref","unstructured":"Bicalutamide, Meyler's Side Effects of Drugs (2016) 967\u2013968. doi:https:\/\/doi.org\/10.1016\/B978-0-444-53717-1.01678-4.","DOI":"10.1016\/B978-0-444-53717-1.01678-4"},{"key":"10.1016\/j.lfs.2024.122697_bb0540","series-title":"Antiandrogen monotherapy in the treatment of prostate cancer","first-page":"515","author":"Piotrowski","year":"2016"},{"key":"10.1016\/j.lfs.2024.122697_bb0545","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2022.08.025","article-title":"Proxalutamide in patients with AR-positive metastatic breast cancer: results from an open-label multicentre phase Ib study and biomarker analysis","volume":"176","author":"Jiang","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lfs.2024.122697_bb0550","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.steroids.2012.01.014","article-title":"Polyproline and Tat transduction peptides in the study of the rapid actions of steroid receptors","volume":"77","author":"Migliaccio","year":"2012","journal-title":"Steroids"},{"key":"10.1016\/j.lfs.2024.122697_bb0555","doi-asserted-by":"crossref","unstructured":"A. Migliaccio, L. Varricchio, A. De Falco, G. Castoria, C. Arra, H. Yamaguchi, A. Ciociola, M. Lombardi, R. Di Stasio, A. Barbieri, A. Baldi, M. V. Barone, E. Appella, F. Auricchio, Inhibition of the SH3 domain-mediated binding of Src to the androgen receptor and its effect on tumor growth, Oncogene 2007 26:46 26 (2007) 6619\u20136629. doi:https:\/\/doi.org\/10.1038\/sj.onc.1210487.","DOI":"10.1038\/sj.onc.1210487"},{"key":"10.1016\/j.lfs.2024.122697_bb0560","doi-asserted-by":"crossref","first-page":"10585","DOI":"10.1158\/0008-5472.CAN-05-0912","article-title":"Steroid receptor regulation of epidermal growth factor signaling through Src in breast and prostate cancer cells: steroid antagonist action","volume":"65","author":"Migliaccio","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.lfs.2024.122697_bb0565","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1158\/1078-0432.CCR-14-2564","article-title":"Combined androgen and estrogen receptor status in breast cancer: treatment prediction and prognosis in a population-based prospective cohort","volume":"21","author":"Elebro","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lfs.2024.122697_bb0570","doi-asserted-by":"crossref","unstructured":"A. Eger, K. Aigner, S. Sonderegger, B. Dampier, S. Oehler, M. Schreiber, G. Berx, A. Cano, H. Beug, R. Foisner, DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells, Oncogene 2005 24:14 24 (2005) 2375\u20132385. doi:https:\/\/doi.org\/10.1038\/sj.onc.1208429.","DOI":"10.1038\/sj.onc.1208429"},{"key":"10.1016\/j.lfs.2024.122697_bb0575","doi-asserted-by":"crossref","unstructured":"J. Liu, H. Ding, H. Quan, J. Han, Anthelminthic niclosamide inhibits tumor growth and invasion in cisplatin-resistant human epidermal growth factor receptor 2-positive breast cancer, Oncol. Lett. 22 (2021). doi:https:\/\/doi.org\/10.3892\/OL.2021.12927.","DOI":"10.3892\/ol.2021.12927"},{"key":"10.1016\/j.lfs.2024.122697_bb0580","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-47707-2","article-title":"Niclosamide reverses adipocyte induced epithelial-mesenchymal transition in breast cancer cells via suppression of the interleukin-6\/STAT3 signalling axis","volume":"9","author":"Gyamfi","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lfs.2024.122697_bb0585","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000019822","article-title":"Effect of Bicalutamide on the proliferation and invasion of human triple negative breast cancer MDA-MB-231 cells","volume":"99","author":"Kong","year":"2020","journal-title":"Medicine"},{"key":"10.1016\/j.lfs.2024.122697_bb0590","doi-asserted-by":"crossref","unstructured":"A.J. Robles, S. Cai, R.H. Cichewicz, S.L. Mooberry, Selective activity of deguelin identifies therapeutic targets for androgen receptor-positive breast cancer, Breast Cancer Research and Treatment 2016 157:3 157 (2016) 475\u2013488. doi:https:\/\/doi.org\/10.1007\/S10549-016-3841-9.","DOI":"10.1007\/s10549-016-3841-9"},{"key":"10.1016\/j.lfs.2024.122697_bb0595","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1200\/jco.2008.26.15_suppl.1009","article-title":"TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer","volume":"26","author":"Carey","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lfs.2024.122697_bb0600","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1200\/jco.2014.32.15_suppl.1133","article-title":"A randomized, parallel-arm, phase II trial to assess the efficacy of preoperative ixabepilone with or without cetuximab in patients with triple-negative breast cancer (TNBC)","volume":"32","author":"Rodriguez","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lfs.2024.122697_bb0605","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/S1470-2045(14)70439-5","volume":"15","author":"von Minckwitz","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lfs.2024.122697_bb0610","unstructured":"Taselisib and enzalutamide in treating patients with androgen receptor positive triple-negative metastatic breast cancer - full text view - ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02457910 (accessed October 20, 2022)."},{"key":"10.1016\/j.lfs.2024.122697_bb0615","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.7150\/ijbs.16176","article-title":"The correlation between PARP1 and BRCA1 in AR positive triple-negative breast Cancer","volume":"12","author":"Luo","year":"2016","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.lfs.2024.122697_bb0620","doi-asserted-by":"crossref","unstructured":"B.A. Gibson, W.L. Kraus, New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs, Nature Reviews Molecular Cell Biology 2012 13:7 13 (2012) 411\u2013424. doi:https:\/\/doi.org\/10.1038\/nrm3376.","DOI":"10.1038\/nrm3376"},{"key":"10.1016\/j.lfs.2024.122697_bb0625","doi-asserted-by":"crossref","unstructured":"T. Maeda, Y. Nakanishi, Y. Hirotani, F. Fuchinoue, K. Enomoto, K. Sakurai, S. Amano, N. Nemoto, Immunohistochemical co-expression status of cytokeratin 5\/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer, Medical Molecular Morphology 2015 49:1 49 (2015) 11\u201321. doi:https:\/\/doi.org\/10.1007\/S00795-015-0109-0.","DOI":"10.1007\/s00795-015-0109-0"},{"key":"10.1016\/j.lfs.2024.122697_bb0630","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0088525","article-title":"Androgen receptor status is a prognostic marker in non-basal triple negative breast cancers and determines novel therapeutic options","volume":"9","author":"Gasparini","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2024.122697_bb0635","doi-asserted-by":"crossref","unstructured":"L.M. Sutton, D. Cao, V. Sarode, K.H. Molberg, K. Torgbe, B. Haley, Y. Peng, Decreased androgen receptor expression is associated with distant metastases in patients with androgen receptor\u2013expressing triple-negative breast carcinoma, Am. J. Clin. Pathol. 138 (2012) 511\u2013516. doi:https:\/\/doi.org\/10.1309\/AJCP8AVF8FDPTZLH.","DOI":"10.1309\/AJCP8AVF8FDPTZLH"},{"key":"10.1016\/j.lfs.2024.122697_bb0640","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1200\/JCO.2016.71.3495","article-title":"Enzalutamide for the treatment of androgen receptor\u2013expressing triple-negative breast cancer","volume":"36","author":"Traina","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lfs.2024.122697_bb0645","unstructured":"Study on androgen receptor and triple negative breast cancer - full text view - ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03383679 (accessed October 20, 2022)."},{"key":"10.1016\/j.lfs.2024.122697_bb0650","unstructured":"Abemaciclib in combination with bicalutamide for androgen receptor-positive, HER2-negative metastatic breast cancer - full text view - ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05095207 (accessed October 20, 2022)."},{"key":"10.1016\/j.lfs.2024.122697_bb0655","unstructured":"Pembrolizumab and enobosarm in treating patients with androgen receptor positive metastatic triple negative breast cancer - full text view - ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02971761 (accessed October 20, 2022)."},{"key":"10.1016\/j.lfs.2024.122697_bb0660","unstructured":"Enzalutamide and paclitaxel before surgery in treating patients with stage I-III androgen receptor-positive triple-negative breast cancer - full text view - ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02689427 (accessed October 20, 2022)."},{"key":"10.1016\/j.lfs.2024.122697_bb0665","unstructured":"Alpelisib and enzalutamide in treating patients with androgen receptor and PTEN positive metastatic breast cancer - full text view - ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03207529 (accessed October 20, 2022)."},{"key":"10.1016\/j.lfs.2024.122697_bb0670","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s10549-021-06109-7","article-title":"The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer","volume":"187","author":"Wardley","year":"2021","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.lfs.2024.122697_bb0675","unstructured":"Ribociclib and bicalutamide in AR+ TNBC - full text view - ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03090165 (accessed October 20, 2022)."},{"key":"10.1016\/j.lfs.2024.122697_bb0680","unstructured":"Efficacy evaluation of enobosarm monotherapy in treatment of AR+\/ER+\/HER2- metastatic breast cancer - full text view - ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04869943 (accessed October 20, 2022)."},{"key":"10.1016\/j.lfs.2024.122697_bb0685","unstructured":"Alpelisib and enzalutamide in treating patients with androgen receptor and PTEN positive metastatic breast cancer - no study results posted - ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT03207529?view=results (accessed January 12, 2023)."},{"key":"10.1016\/j.lfs.2024.122697_bb0690","unstructured":"PAveMenT: palbociclib and avelumab in metastatic AR+ triple negative breast cancer. https:\/\/clin.larvol.com\/trial-detail\/NCT04360941\/279802 (accessed January 12, 2023)."},{"key":"10.1016\/j.lfs.2024.122697_bb0695","unstructured":"Efficacy & safety evaluation of enobosarm in combo with abemaciclib in treatment of ER+HER2- metastatic breast cancer - no study results posted - ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT05065411 (accessed January 12, 2023)."},{"key":"10.1016\/j.lfs.2024.122697_bb0700","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1158\/1078-0432.CCR-12-3327","article-title":"Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer","volume":"19","author":"Gucalp","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lfs.2024.122697_bb0705","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/CAD.0000000000000880","article-title":"Combination treatment of bicalutamide and curcumin has a strong therapeutic effect on androgen receptor-positive triple-negative breast cancers","volume":"31","author":"Dong","year":"2020","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.lfs.2024.122697_bb0710","unstructured":"Bicalutamide in treating patients with metastatic breast cancer - study results - ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT00468715 (accessed October 19, 2022)."},{"key":"10.1016\/j.lfs.2024.122697_bb0715","unstructured":"A Study to evaluate changes in human breast cancer tissue following short-term use of darolutamide - study results - ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT03004534 (accessed October 19, 2022)."},{"key":"10.1016\/j.lfs.2024.122697_bb0720","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/onco.13583","article-title":"A phase II clinical trial of Pembrolizumab And Enobosarm in patients with androgen receptor-positive metastatic triple-negative breast cancer","volume":"26","author":"Yuan","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.lfs.2024.122697_bb0725","unstructured":"Efficacy and safety of GTx-024 in patients with estrogen receptor (ER)+\/androgen receptor (AR)+ breast cancer - study results - ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT02463032 (accessed October 19, 2022)."},{"key":"10.1016\/j.lfs.2024.122697_bb0730","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/annonc\/mdv487","article-title":"Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptorpositive metastatic breast cancer","volume":"27","author":"O\u2019Shaughnessy","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lfs.2024.122697_bb0735","series-title":"Results From a Phase 2 Study of Enzalutamide (ENZA), an Androgen Receptor (AR) Inhibitor, in Advanced AR+ Triple-Negative Breast Cancer (TNBC)","first-page":"1003","author":"Traina","year":"2015"},{"key":"10.1016\/j.lfs.2024.122697_bb0740","unstructured":"Orteronel as monotherapy in patients with metastatic breast cancer (MBC) that expresses the androgen receptor (AR) - study results - ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT01990209?view=results (accessed October 19, 2022)."},{"key":"10.1016\/j.lfs.2024.122697_bb0745","unstructured":"Abiraterone acetate in treating postmenopausal women with advanced or metastatic breast cancer - full text view - ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00755885 (accessed October 19, 2022)."},{"key":"10.1016\/j.lfs.2024.122697_bb0750","unstructured":"Phase II Study of GTx024 in women with metastatic breast cancer - full text view - ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01616758 (accessed October 19, 2022)."},{"key":"10.1016\/j.lfs.2024.122697_bb0755","first-page":"141","article-title":"Drug resistance and combating drug resistance in cancer","volume":"2","author":"Wang","year":"2019","journal-title":"Cancer Drug Resistance"},{"key":"10.1016\/j.lfs.2024.122697_bb0760","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.3390\/curroncol28030168","article-title":"Current landscape of targeted therapy in hormone receptor-positive and HER2-negative breast cancer","volume":"28","author":"Andrahennadi","year":"2021","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.lfs.2024.122697_bb0765","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3747\/co.25.3752","article-title":"Overcoming endocrine resistance in hormone receptor\u2013positive breast cancer","volume":"25","author":"AlFakeeh","year":"2018","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.lfs.2024.122697_bb0770","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2024.122697_bb0775","doi-asserted-by":"crossref","first-page":"4675","DOI":"10.2147\/OTT.S126051","article-title":"Targeting the androgen receptor in triple-negative breast cancer: current perspectives","volume":"10","author":"Mina","year":"2017","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.lfs.2024.122697_bb0780","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1158\/1541-7786.MCR-17-0480","article-title":"AR expression in breast cancer CTCs associates with bone metastasesa role for AR in breast cancer bone metastasis","volume":"16","author":"Aceto","year":"2018","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.lfs.2024.122697_bb0785","doi-asserted-by":"crossref","first-page":"16759","DOI":"10.1073\/pnas.1012443107","article-title":"Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor","volume":"107","author":"Watson","year":"2010","journal-title":"National Acad Sciences"},{"key":"10.1016\/j.lfs.2024.122697_bb0790","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1158\/0008-5472.CAN-08-3795","article-title":"A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth","volume":"69","author":"Guo","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.lfs.2024.122697_bb0795","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0019059","article-title":"Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival","volume":"6","author":"H\u00f6rnberg","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2024.122697_bb0800","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.6296","article-title":"Expression of androgen receptor splice variants in clinical breast cancers","volume":"6","author":"Hickey","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.lfs.2024.122697_bb0805","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/(SICI)1097-0215(19970807)72:4<574::AID-IJC4>3.0.CO;2-N","article-title":"Identification of an exon 3 deletion splice variant androgen receptor mRNA in human breast cancer","volume":"72","author":"Zhu","year":"1997","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.lfs.2024.122697_bb0810","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ctrv.2017.09.006","article-title":"Androgen receptor in estrogen receptor positive breast cancer: beyond expression","volume":"61","author":"Basile","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.lfs.2024.122697_bb0815","doi-asserted-by":"crossref","unstructured":"J. Wang, J.X. Zou, X. Xue, D. Cai, Y. Zhang, Z. Duan, Q. Xiang, J.C. Yang, M.C. Louie, A.D. Borowsky, A.C. Gao, C.P. Evans, K.S. Lam, J. Xu, H.J. Kung, R.M. Evans, Y. Xu, H.W. Chen, ROR-\u03b3 drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer, Nature Medicine 2016 22:5 22 (2016) 488\u2013496. doi:https:\/\/doi.org\/10.1038\/nm.4070.","DOI":"10.1038\/nm.4070"},{"key":"10.1016\/j.lfs.2024.122697_bb0820","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1158\/0008-5472.CAN-15-2186","article-title":"Second-generation HSP90 inhibitor onalespib blocks mRNA splicing of androgen receptor variant 7 in prostate cancer cells","volume":"76","author":"Ferraldeschi","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.lfs.2024.122697_bb0825","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1159\/000110458","article-title":"Activation of FAK\/PI3K\/Rac1 signaling controls actin reorganization and inhibits cell motility in human cancer cells","volume":"20","author":"Kallergi","year":"2007","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.lfs.2024.122697_bb0830","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.molonc.2010.01.004","article-title":"Testosterone membrane-initiated action in breast cancer cells: interaction with the androgen signaling pathway and EPOR","volume":"4","author":"Pelekanou","year":"2010","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.lfs.2024.122697_bb0835","doi-asserted-by":"crossref","first-page":"5406","DOI":"10.1093\/emboj\/19.20.5406","article-title":"Steroid-induced androgen receptor\u2013oestradiol receptor \u03b2\u2013Src complex triggers prostate cancer cell proliferation","volume":"19","author":"Migliaccio","year":"2000","journal-title":"EMBO J."},{"key":"10.1016\/j.lfs.2024.122697_bb0840","first-page":"719","article-title":"Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity","volume":"104","author":"Kousteni","year":"2001","journal-title":"Cell"},{"key":"10.1016\/j.lfs.2024.122697_bb0845","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jsbmb.2010.10.009","article-title":"Hypoxia enhances transcriptional activity of androgen receptor through hypoxia-inducible factor-1\u03b1 in a low androgen environment","volume":"123","author":"Mitani","year":"2011","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.lfs.2024.122697_bb0850","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-07411-7","article-title":"Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen\/AR-targeted therapy","volume":"9","author":"Geng","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.lfs.2024.122697_bb0855","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-020-06890-6","article-title":"Independence of HIF1a and androgen signaling pathways in prostate cancer","volume":"20","author":"Tran","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.lfs.2024.122697_bb0860","doi-asserted-by":"crossref","first-page":"8844","DOI":"10.3390\/ijms23168844","article-title":"Adaptation to hypoxia may promote therapeutic resistance to androgen receptor inhibition in triple-negative breast cancer","volume":"23","author":"Jinna","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2024.122697_bb0865","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s10549-014-3082-8","article-title":"AR collaborates with ER\u03b1 in aromatase inhibitor-resistant breast cancer","volume":"147","author":"Rechoum","year":"2014","journal-title":"Breast Cancer Res. Treat."}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002432052400287X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002432052400287X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,19]],"date-time":"2024-05-19T11:53:58Z","timestamp":1716119638000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002432052400287X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":173,"alternative-id":["S002432052400287X"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2024.122697","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Androgen receptor: Structure, signaling, function and potential drug discovery biomarker in different breast cancer subtypes","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2024.122697","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"122697"}}